Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 161 participants.

Also called NCT01212913

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 161 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01212913
Other papers using this trial's data
  • Basal-prandial versus premixed insulin in patients with type 2 diabetes requiring insulin intensification after basal insulin optimization: A 24-week randomized non-inferiority trial Journal of diabetes, 2016-05 DOI, PubMed 25952532

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01212913. Randomized; no masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2012-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)
Acronym
B to B
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
INSULIN GLARGINE
Intervention (Drug)
INSULIN GLULISINE
Intervention (Drug)
Insulin aspart
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01212913
Content hash
3342afb293ef575cc10f1afb0a9f186db032a310342a7cbc2daf73577b6b6b73